Concepedia

Frederick Briccetti

FB

9

Publications

627

Citations

9

H-Index

1993

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

University of North Carolina at Chapel Hill

University of Chicago

Harvard University

Cornell University

Frederick Briccetti is an author at Dana-Farber Cancer Institute specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

1993–2024

9

Publications

9

Analysis of CD36 Binding Domains: Ligand Specificity Controlled by Dephosphorylation of an Ectodomain

Adam S. Asch, Isaac Liu, Frederick Briccetti et al. · Science · 1993 · 219 citations

, , +19

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan et al. · Blood · 2008 · 143 citations · Full text

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Sara M. Tolaney, Nabihah Tayob, Chau T. Dang et al. · Journal of Clinical Oncology · 2021 · 131 citations · Full text

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob et al. · Breast Cancer Research and Treatment · 2021 · 34 citations

, , +8

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

Wendy Y. Chen, Karla V. Ballman, Ann H. Partridge et al. · JAMA · 2024 · 29 citations · Full text

Rows per page

1–5 of 9